RxDoctor Payments Data

Thomas Russell, MD

Ophthalmology · Dallas, TXNPI 1770539967

Payments from drug & device makers

$4,252in general payments, 2019–2025

Across 145 payments — averaging $29.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$964
  • Alcon$432
  • Carl Zeiss Meditec USA, Inc.$304
  • Eyevance Pharmaceuticals LLC$281
  • NEW World Medical,inc.$279
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$246
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$4,22699%
  • Education$70%
  • Gifts$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,252 in reported general payments places this provider in the 65th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$432,547
Medicare patients
1,058
Services billed
2,908

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast36$33,441
RestasisCyclosporine21$26,406
LumiganBimatoprost48$21,381
MieboPerfluorohexyloctane/Pf18$14,417
VevyeCyclosporine12$13,445
Prednisolone Acetate261$11,535
Loteprednol Etabonate35$4,785
Fluorometholone58$3,786
Tobradex StTobramycin/Dexamethasone16$3,659
Travoprost21$3,076
Tobramycin-DexamethasoneTobramycin/Dexamethasone60$2,635
Brimonidine Tartrate35$2,403
Diclofenac Sodium274$2,386
Latanoprost267$2,371
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol11$2,271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Miebo$186$47,85854 claims
AbbVieRestasis, Lumigan$964$47,78769 claims
Eyevance Pharmaceuticals LLCTobradex St, Flarex$281$5,36029 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$246$4,78535 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →